Compositions and methods for reducing body fat

Details Compositions and methods for reducing body fat Compositions and methods for reducing body fat

2007-03-01

2010-02-23

Padmanabhan, Screeni (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C564S171000

Reexamination Certificate

active

07666912

ABSTRACT:
The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.

REFERENCES:
patent: 4599353 (1986-07-01), Bito
patent: 5011062 (1991-04-01), Nakanishi et al.
patent: 5296504 (1994-03-01), Stjernschantz et al.
patent: 5422368 (1995-06-01), Stjernschantz et al.
patent: 5631287 (1997-05-01), Schneider
patent: 5688819 (1997-11-01), Woodward et al.
patent: 5849792 (1998-12-01), Schneider
patent: 5889052 (1999-03-01), Klimko et al.
patent: 6235781 (2001-05-01), Weiner et al.
patent: 6403649 (2002-06-01), Woodward et al.
patent: 6646001 (2003-11-01), Hellberg et al.
patent: 6730707 (2004-05-01), Pintor et al.
patent: 6864282 (2005-03-01), Ling et al.
patent: 6933289 (2005-08-01), Lyons et al.
patent: 7070768 (2006-07-01), Krauss
patent: 7125542 (2006-10-01), Miller et al.
patent: 7351404 (2008-04-01), Woodward et al.
patent: 2004/0082660 (2004-04-01), Ueno
patent: 2005/0058614 (2005-03-01), Krauss
patent: WO-03/66008 (2003-08-01), None
patent: WO-2005/034889 (2005-04-01), None
patent: WO-2005/034890 (2005-04-01), None
patent: WO-2007/111806 (2007-10-01), None
Lepak et al. (1993) Inhibition of Adipose Differentiation by 9α, 11β—Prostaglandin F2α Prostaglandins 46:511-517.
Serrero et al. (1995), Prostaglandin F2α Inhibits Epidermal Growth Factor Binding To Cellular Receptors on Adipocyte Precursors in Primary Culture, Biochem. Biophys. Res. Commun. 212:1125-1132.
Lepak et al., Prostaglandin F2α Stimulates Transforming Growth Factor-α Expression in Adipocyte Precursors, (1995) Endocrinology 136:3222-3229).
Kegg Drug: D02724, [online] retrieved on Nov. 30, 2007, (2007), retrieved from http://www.genome.ad.jp/dbget-bin/www—bget?drug+D02724 and http://www.genome.ad.jp/dbget-bin/www—bget?pathway+map07035, printed p. 1 and printed pp. 1-3, respectively.
Holmstrom et al. (Analytic Review of Bimatoprost, Latanoprost, and Travoprost in primary open angle glaucoma, Current Medical Research and Opinion (2005), vol. 21, iss. 11; p. 1875, 9 printed pages.
Entrepreneur.com Prostaglandin analogues (online: http://www.entrepreneur.com/tradejournals/article/print/166777491.html,2008, printed pp. 1 and 2, especially p. 1).
International Search Report for Application No. PCT/US2007/005424, published Feb. 7, 2008 (6 pages).
Baer et al. (1993) “Measurement of Body Composition of Live rats by Electromagnetic Conductance,”Physiol. &Behav. 53:1195-99.
Bertin et al. (1998) “Evaluation of Dual-Energy X-Ray Absorptiometry for Body-Composition Assessment in Rats,”J. Nutrition128: 1550-54.
Casimir et al. (1996) “Preadipocyte Differentiation Blocked by Prostaglandin Stimulation of Prostanoid FP2Receptor in Murine 3T3-L1 Cells,”Differentiation60: 203-210.
Culebras et al. (1977) “Total Body Water and the Exchangeable Hydrogen. II. A Review of Comparative Data from Animals Based on Isotope Dilution and Desiccation, with a Report of New Data from the Rat,”Am. J. Physiol. Regulatory Integrative Comp. Physiol. 232: 60-65.
Dahms et al. (1982) “Correlation of Percent Body Fat with Body Specific Gravity in Rats,”J. Nutrition112: 398-400.
Frisch et al. (1977) “Carcass Components at First Estrus of Rats on High-fat and Low-fat Diets: Body Water, Protein, and Fat,”PNAS(USA) 74: 379-83.
Gorin et al. (1990) “Evidence for a Role of Protein Kinase C in the Stimulation of Lipolysis by Growth Hormone and Isoproterenol,”Endocrinology126(6): 2973-82.
Grosskreutz, Abstract submitted on Nov. 1, 2005 to the American Glaucoma Society for the American Glaucoma Society 2006 Annual Meeting (1 page).
Grosskreutz et al., “Periorbital Fat Loss and Eyelid Sulcus Deepening after Bimatoprost Therapy,” Final Program and Abstract Book, pp. 49 and 53, distributed at The American Glaucoma Society 2006 Annual Meeting, Mar. 2-5, 2006.
Grosskreutz et al., “Periorbital Fat Loss and Eyelid Sulcus Deepening after Bimatoprost Therapy,” poster presented at The American Glaucoma Society 2006 Annual Meeting, Charleston, South Carolina, Mar. 2-5, 2006 (1 page).
Husain et al. (2005) “Acute Effects of PGF2αon MMP-2 Secretion from Human Ciliary Muscle Cells: a PKC- and ERK-Dependent Process,”Invest. Ophthalmol. Vis. Sci. 46(5):1706-13.
Kunnecke et al. (2004) “Quantitative Body Composition Analysis in Awake Mice and Rats by Magnetic Resonance Relaxometry,”Obes. Res. 12: 1604-15.
Lepak et al. (1993) “Inhibition of Adipose Differentiation by 9α, 11β-prostaglandin F2α,”Prostaglandins46: 511-17.
Lepak et al. (1995) “Prostaglandin F2αStimulates Transforming Growth Factor- α Expression in Adipocyte Precursors,”Endocrinology136(8): 3222-29.
Lin et al. (2005) “Green Tea Polyphenol Epigallocatechin Gallate Inhibits Adipogenesis and Induces Apoptosis in 3T3-L1 Adipocytes,”Obesity Res. 13(6): 982-90.
FDA CDER Approval Letter (3 pages) and Toxicology Study #5 from CDER Pharmacology Review (cover page and pp. 43-44 of 107 included) for Lumigan (Bimatoprost Ophthalmic Solution), NDA Application No. 21-275 (FDA Approval Date: Mar. 16, 2001), available at http://www.fda.gov/cder/foi
da/2001/21275—Lumigan.htm (last visited May 23, 2008).
Maxey et al. (2002) “The Hydrolysis of Bimatoprost in Corneal Tissue Generates a Potent Prostanoid FP Receptor Agonist,”Surv. Ophthalmol. 47(Supp.1): S34-40.
Miller et al. (1996) “The Mechanism of Inhibition of 3T3-L1 Preadipocyte Differentiation by Prostaglandin F2α,”Endocrinology137(12): 5641-50.
Paula et al. “Periorbital Fat Loss and Eyelid Sulcus Deepening after Bimatoprost Therapy,” manuscript submitted toArchives of Ophthalmology, Oct. 21, 2005 (10 pages).
Peplinski et al. (2004) “Deepening of Lid Sulcus from Topical Bimatoprost Therapy,”Optom. Vis. Sci. 81(8): 574-77.
Robin (2002) “An accurate Comparison of Bimatoprost's Efficacy and Adverse Effects,”Arch. Ophthalmol. 120(7): 999-1000.
Rundle, Rhonda L., “Drug That Lengthens Eyelashes Sets Off Flutter,”Wall Street J. Nov. 19, 2007 (2 pages).
Serrero et al. (1992) “Prostaglandin F2α Inhibits the Differentiation of Adipocyte Precursors in Primary Culture,”Biochem. Biophys. Res. Commun. 183: 438-42.
Serrero et al. (1995) “Prostaglandin F2α, Inhibits Epidermal Growth Factor Binding to Cellular Receptors on Adipocyte Precursors in Primary Culture,”Biochem. Biophys. Res. Commun. 212: 1125-32.
Serrero et al. (1997) “Prostaglandin F2αReceptor (FR Receptor) Agonists Are Potent Adipose Differentiation Inhibitors for Primary Culture of Adipocyte Precursors in Defined Medium,”Biochem. Biophys. Res. Commun. 233: 200-2.
Tsuboi et al. (2004) “Prostanoid EP4 Receptor is Involved in Suppression of 3T3-L1 Adipocyte Differentiation,”Biochem. Biophys. Res. Commun. 322: 1066-72.
Excerpts from Wanna Be Big Bodybuilding and Weightlifting Forums: Community Central <http://www.wannabebigforums.com/archive/index.php/f-20.html>/ General Chat <http://www.wannabebigforums.com/archive/index.php/f-12.html>/The Myostatin Gene, posted at 4:22pm, Feb. 5, 2001, by Cackerot69, http://www.wannabebigforums.com/archive/index.php/t-359.html (4 pages).
Excerpts from BodybuildingForYou—Bodybuilding Forums: Anabolic Steroids/Prohormones, and Testosterone Enhancers <http://www.bodybuildingforyou.com/forums/anabolic-steroids-prohormones-testosterone-enhancers/>/ Anabolic Steroids & Anabolic Chemistry & Testosterone Enhancers <http://www.bodybuildingforyou.com/forums/anabolic-steroids-anabolic-chemistry-testosterone-enhancers/>/ Anabolic Steroid, HGH, IGF, Insulin and Ancillary Profiles, pgf2a parts 3-5, post Nos. 35-37 by RRAdam on Jul. 12, 200

Affiliated with

Also associated with

Rating

Compositions and methods for reducing body fat does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for reducing body fat, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for reducing body fat will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4153654